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Abstract 
Mutations in the human MMAA gene cause the metabolic disorder cblA-type methylmalonic 
aciduria (MMA), although knowledge of the mechanism of dysfunction remains lacking. 
MMAA regulates the incorporation of the cofactor adenosylcobalamin, generated from the 
MMAB adenosyltransferase, into the destination enzyme methylmalonyl-CoA mutase (MUT). 
This function of MMAA depends on its GTPase activity, which is stimulated by an interaction 
with MUT. Here, we present 67 new patients with cblA-type MMA, identifying 19 novel 
mutations. We investigated biochemically how 22 patient missense mutations in MMAA lead 
to disease. About a third confer instability to the recombinant protein in bacterial and human 
expression systems. All 15 purified mutant proteins demonstrated wild-type like intrinsic 
GTPase activity and only one (p.Asp292Val), where the mutation is in the GTP binding domain, 
revealed decreased GTP binding. However, all mutations strongly decreased functional 
association with MUT by reducing GTPase activity stimulation upon incubation with MUT, 
while 9 mutant proteins additionally lost the ability to physically bind MUT. Finally, all 
mutations interfered with gating the transfer of adenosylcobalamin from MMAB to MUT. This 
work suggests loss of functional interaction between MMAA and MUT as a disease causing 
mechanism that impacts processing and assembly of a cofactor to its destination enzyme. 
 
Key words: vitamin B12; MMAA; cblA-type methylmalonic aciduria, protein-protein 
interaction; missense variants, patient cohort; methylmalonyl-CoA mutase;  
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Introduction 
In humans, vitamin B12 (cobalamin, Cbl) is modified through various steps to function as a 
cofactor for two enzymes, methionine synthase in the cytosol, which utilizes methylcobalamin, 
and methylmalonyl-CoA mutase (MUT, MIM# 609058, EC 5.4.99.2) in the mitochondria, 
requiring adenosylcobalamin (AdoCbl). The distinct modifications required to produce the 
correct Cbl cofactor forms and the different subcellular locations of the two enzymes have led 
to the emergence of a finely-tuned pathway ensuring correct uptake, processing and delivery of 
Cbl to these destination enzymes. MUT is responsible for the rearrangement of methylmalonyl-
CoA to succinyl-CoA, which enters the tricarboxylic acid cycle. This reaction is a main step in 
propionate catabolism, as it funnels metabolites from the breakdown of branched-chain amino 
acids, odd-chain fatty acids, and the side chain of cholesterol into the tricarboxylic acid cycle 
(Fowler et al. 2008). In the multi-player process of AdoCbl delivery to MUT, the protein 
MMAB (MIM# 607568, EC 2.5.1.17), an ATP:cob(I)alaminadenosyltransferase (Dobson et al. 
2002a; Leal et al. 2004), produces AdoCbl in an ATP-dependent transfer, while MMAA (MIM# 
607481, EC:2.7.-.-.) is responsible for proper AdoCbl incorporation into MUT through a GTP-
dependent interaction (Padovani et al. 2006; Padovani and Banerjee 2009). 
MMAA is a small G-protein belonging to the G3E family of P-loop GTPases (Leipe et al. 2002). 
It consists of a central G-domain, which encompasses the four GTPase signature motifs (Switch 
I, Switch II, P-loop and base specificity loop), flanked by an N-terminal extension and a C-
terminal dimerization arm (Froese et al. 2010). MMAA is highly conserved from bacteria to 
human, and studies in the Methylobacterium extorquens (M. ext.) ortholog MeaB, which has a 
similar monomeric structure, has provided many insights into the function of MMAA (Hubbard 
et al. 2007). Interaction between MMAA and MUT was first shown using their M. ext. orthologs 
MeaB and MCM, respectively (Korotkova and Lidstrom 2004; Padovani et al. 2006). 
Furthermore, these homologs have been used to show stimulation of MeaB GTPase activity 
upon MCM binding, the importance of the GTPase activity of MeaB to gate AdoCbl 
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incorporation into MCM by blocking unproductive conformations and the ejection of oxidized 
cobalamin from MCM by MeaB (Padovani and Banerjee 2006, 2009). 
Nevertheless, important differences between MMAA and MeaB, as well as MUT and MCM, 
remain. For example, although MMAA and MeaB protomers have a similar structure, their 
homodimeric structures show marked differences (Froese et al. 2010). Likewise, although MUT 
functions as a homodimer of two catalytic subunits, MCM is heterodimeric with only one 
catalytic subunit (Froese et al. 2010). These differences suggest that human MMAA and MUT 
may interact in a manner distinct from their bacterial counterparts. Indeed, investigations into 
the oligomeric assembly and ligand requirements for the interaction of the human proteins show 
they are different from that of MeaB and MCM (Hubbard et al. 2007; Froese et al. 2010). 
Therefore, although much can be inferred about the function of MMAA from its bacterial 
homolog, there is still much to discover. 
A disturbed function of MMAA caused by autosomal recessive mutations in the MMAA gene 
results in methylmalonic aciduria (MMA) of the cblA-type (OMIM: 251100) (Dobson et al. 
2002b). Clinically, disease presentation is almost identical to that of MUT deficiency (MMA 
mut-type; OMIM: 251000), although usually somewhat milder (Hörster et al. 2007). For each, 
symptoms vary widely, presenting in neonates through to adulthood with a range of symptoms, 
including recurrent vomiting, failure to thrive, progressive renal dysfunction and neurologic 
complications. If untreated, metabolic crisis can result in lethal multi-organ failure, underlining 
the importance of improving the knowledge about disease pathology (Matsui et al. 1983; 
Hörster et al. 2007). To date, about 140 cblA patients harbouring 41 different mutations in 
MMAA have been published (Rosenberg et al. 1968; Ampola et al. 1975; Gravel et al. 1975; 
Matsui et al. 1983; Dobson et al. 2002b; Yang et al. 2004; Lerner-Ellis et al. 2004; Martínez et 
al. 2005; Hörster et al. 2007; Merinero et al. 2008; Dempsey-Nunez et al. 2012; Vatanavicharn 
et al. 2012; Nizon et al. 2013). The nonsense mutation c.433C>T (p.Arg145*), resulting in a 
premature stop-codon, accounts for the majority of pathogenic alleles (Lerner-Ellis et al. 2004). 
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Biochemical analysis of the MMAA patient missense mutation p.Gly188Arg demonstrated 
impaired complex formation with MUT as its only discernible defect (Froese et al. 2010), 
highlighting the importance of this interaction for B12 pathway function, and suggesting that 
other mutations may result in a similar dysfunction.  
In this study, we present data from 67 unpublished patients with cblA-type MMA, from which 
19 novel mutations in the MMAA gene were identified. Analysis of all known MMAA missense 
mutations to date indicate that about one third confer instability to the protein and the rest show 
a markedly reduced ability to functionally interact with MUT, which further affects the transfer 
of AdoCbl from MMAB to MUT. This work suggests that it is not loss of MMAA activity that 
causes disease, but rather lost interaction with MUT. 
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Materials and Methods 
Genotyping 
Skin fibroblasts or blood samples were taken from patients with biochemical and clinical 
evidence of cblA-type MMA, referred to our institution for diagnostic purposes. The study has 
been approved by the ethics commission of the Canton of Zurich, Switzerland (application no. 
2014-0211). Genomic DNA (gDNA) extraction from cultured patient ﬁbroblasts was performed 
using the QIAamp DNA Mini Kit and from EDTA blood using the DNEasy Blood and Tissue 
Kit (Qiagen, Venlo, The Netherlands). RNA extraction was performed using the RNeasy Mini 
Kit (Qiagen). Mutations were identified by amplification of exons by PCR from gDNA using 
ﬂanking intronic primers and sequencing using the ABI BigDye method (Applied Biosystems, 
Thermo Fisher Scientific, CA, USA). The nomenclature of the mutations is based on the cDNA 
sequence NM 172250.2. Nucleotide numbering uses +1 as the A of the ATG translation 
initiation codon in the reference sequence, with the initiation codon as codon 1. All of the 
variants in Table 1 were submitted to the freely accessible NCBI ClinVar Database 
http://www.ncbi.nlm.nih.gov/clinvar/ using the standard HGVS nomenclature. 
Propionate Incorporation Assay 
Patient fibroblasts were cultured in Earle’s minimal essential medium (Gibco, Carlsbad, CA; 
USA) supplemented with 10% fetal calf serum (Gibco), 2 mM L-glutamine (Gibco), and 
antibiotics (GE Healthcare, Little Chalfont, UK), as described earlier (Suormala et al. 2004). 
Incorporation of 14C-propionate was assayed in cultured skin fibroblasts grown in the presence 
or absence of hydroxycobalamin (OH-Cbl; 1 or 10 mg/L) and was performed as described 
previously (Suormala et al. 2004) by a slightly modified method of Willard et al. 1976. 
Cloning 
For expression in E. coli, we used previously described constructs of MMAA, encompassing 
amino acids 73-424 in the pNIC28-Bsa4 vector, and MUT, encompassing amino acids 12-750 
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in the pNIC-CTHF vector (Froese et al. 2010), resulting in constructs without the mitochondrial 
localization sequence. For MMAB expression, a DNA fragment encoding N-terminally 
truncated MMAB (amino acids 51-250, no mitochondrial localization sequence) was subcloned 
from IMAGE clone 3938643 into the pNIC28-Bsa4 vector. For expression in HEK293 cells, a 
DNA fragment encoding full length MMAA (IMAGE clone 40017263) was subcloned into the 
vector pCDNA3-C-Flag-LIC using LIC cloning. Site directed mutagenesis was carried out 
using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) as 
described in the manufacturer’s instructions, using forward and reverse primers (Microsynth, 
Balgach, Switzerland) and confirmed by Sanger sequencing. All primers are available upon 
request. 
Bacterial expression and purification 
Wild-type and mutant MMAA, as well as MUT and MMAB, were expressed in E. coli and 
purified by affinity (Ni-NTA; Qiagen) and size-exclusion (Superdex 200; GE Healthcare) 
chromatography as described in Froese et al. (2010). Small-scale purification of wt MMAA and 
all mutants was performed as described in Forny et al. (2014). For large scale purification cells 
were grown in a total of 12 L, then harvested by centrifugation at 5000 x g for 10 min and lysed 
with a Badelin Sonoplus HD2070 homogenizer. Insoluble material was clarified by 
centrifugation at 5000 x g and the supernatant purified by affinity (Ni-NTA, Qiagen) and size-
exclusion (Superdex 200; GE Healthcare) chromatography as described in Froese et al. (2010). 
Transfection and expression in HEK293 cells 
HEK293 cells were transiently transfected with pCDNA3-C-Flag-LIC-MMAA wt and mutant 
constructs using electroporation (Baumgartner et al. 2001) and grown in Dulbecco’s Modified 
Eagle Medium (Gibco) supplemented with 10% fetal bovine serum (Gibco) and antibiotics (GE 
Healthcare), as previously described (Suormala et al. 2004). Cells were harvested by 
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trypsinization 48 hours after electroporation, washed twice with HBSS (Gibco) and either 
frozen at -20°C or processed directly.  
Immunoprecipitation and Immunoblotting 
Cell lysis was performed on fresh or frozen pellets resuspended in 5 mM potassium phosphate 
buffer (pH 7.4) via sonication twice at amplitude 1.5 for 15 sec using the microprobe of an XL-
2000 sonicator (Microson, Qsonica New-town, CT, USA). For immunoprecipitation, only fresh 
cell pellets were used. Cells were resuspended in lysis buffer (1% Nonidet P-40, 0.5% 
deoxycholine, 150 mM NaCl, 50 mM Tris-HCl, pH 7.5) supplemented with 250 µM MgCl2 
(Sigma–Aldrich, Buchs SG, Switzerland) and 100 µM GMPPNP (Sigma–Aldrich) for 10 
minutes and then centrifuged at 10000 x g for 5 min. Immunoprecipitation with anti-Flag or 
IgG antibody (Sigma–Aldrich) was performed using Dynabeads Protein G (Life Technologies, 
Carlsbad, CA, USA) according to the manufacturer’s instructions and immunoblotted with anti-
Flag or anti-MUT antibodies. Western Blot was performed on fresh or frozen cell pellets 
essentially as described in Forny et al. (2014), with the addition of the monoclonal anti-flag M2 
(1:2000, Sigma–Aldrich) antibody used to detect MMAA-flag. 
Binding of GTP nucleotide to MMAA 
Binding of GTP to MMAA was measured by titration of wt MMAA or mutants (10-110 µM) 
to 10 µM mant-GTP (2'/3'-O-(N-Methyl-anthraniloyl)-guanosine-5'-triphosphate) (Sigma–
Aldrich) in buffer containing 100 mM HEPES pH7.5, 300 mM KCl and 5% glycerol. Mant-
GTP binding was measured as change in fluorescence intensity. The fluorescence emission was 
measured at 440 nm with an excitation of 360 nm using a Synergy HT plate reader (Biotek, 
Luzern, Switzerland). Fluorescence data were fit in GraphPad Prism (v6.07, GraphPad 
Software, Inc.). 
Kinetics of MMAA GTP hydrolysis 
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Intrinsic GTPase activity of wt MMAA and mutants (20 µM) was evaluated in the presence of 
1000 µM GTP (Sigma–Aldrich) by the Enzchek Phosphate Assay (Molecular Probes, Eugene, 
Oregon, USA) following manufacturer’s instructions. First, the reaction mixture was incubated 
in presence of 1000 µM GTP for 20 minutes without enzyme to generate a baseline. Then wt 
MMAA and mutants (20 µM) were added to the reaction mixture and the increase in absorbance 
at 360 nm monitored for 20 minutes using a Synergy HT plate reader (Biotek). GTPase activity 
in wt MMAA and MUT was determined by incubating either wt MMAA (20 µM), MUT (20 
µM), or both (20 µM each) in the presence of various concentrations of GTP (100–2500 µM, 
Sigma–Aldrich) and monitoring the increase in absorbance for 20 minutes. The same approach 
was used for determining GTPase activity of MMAA mutants (20 µM), which were incubated 
in the presence of 20 µM MUT. Calculation of Michelis-Menten kinetics was performed using 
GraphPad Prism (v6.07, GraphPad Software, Inc.) as previously described (Froese et al. 2010). 
Differential Scanning Fluorimetry 
Purified mutant and wt MMAA proteins were diluted to 0.1 mg/ml in buffer (10 mM HEPES 
pH 7.5, 150 mM NaCl, 5% glycerol) with 1:1000 Sypro Orange (Invitrogen, Carlsbad, CA, 
USA) and 25 µM MgCl2 (Sigma–Aldrich) and run in the apo-state or with pre-incubation of 0-
2000 µM GDP (Sigma–Aldrich) or 0-5000 µM GMPPNP (Sigma–Aldrich) on a LightCycler® 
480 machine (Roche, Basel, Switzerland). Shifts in melting temperature (ΔTm), final graphs 
and the AC50 for each protein-ligand pair were calculated using GraphPad Prism (v6.07, 
GraphPad Software, Inc.) software. 
Size Exclusion Chromatography 
Analytical gel filtration was performed using a Superdex 200 HiLoad 10/30 column (GE 
Healthcare) pre-equilibrated with buffer containing 100 mM HEPES pH7.5, 300 mM KCl and 
5% glycerol. Samples were prepared in the same buffer with 250 µM MgCl2 (Sigma–Aldrich) 
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and 100 µM GMPPNP (Sigma–Aldrich) added. Calibration of the column was performed using 
carbonic anhydrase (29 kDa), bovine serum albumin (66 kDa), alcohol dehydrogenase (150 
kDa), and apo-ferritin (443 kDa) (Sigma–Aldrich) as MW-standards. 
UV-Visible Spectroscopy 
The release of AdoCbl was monitored by adding ATP (5-1750 μM) to holo-MMAB (60 μM 
bound AdoCbl) in buffer containing 100 mM HEPES pH 8.0, 300 mM KCl, 10 mM MgCl2 and 
5% glycerol. After mixing, spectral curves were recorded from 300-700 nm and cofactor release 
was monitored at 525 nm. The release of AdoCbl from holo-MMAB was also measured in the 
presence of MUT (60 μM), wt MMAA (60 μM) or MMAA mutants (60 μM) and in the presence 
of GTP, GDP and GMPPNP (0.5 mM, Sigma–Aldrich). 
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Results 
Clinical features and mutation analysis of patients with cblA-type MMA 
We present data from 67 previously unpublished cblA-type patients, listed in Table 1 and 
including the sex, age of onset, propionate incorporation profiles and mutations found in these 
individuals. In this patient cohort, we found 34 different mutations in the MMAA gene: 11 
missense mutations, 10 frameshifts, 8 nonsense mutations, 4 splice-site defects, and 1 deletion. 
Of these, 19 represented novel mutations (in bold in Table 1). Of those mutations identified in 
more than one individual the most frequent was c.433C>T (p.Arg145*), identified in 25 alleles, 
accounting for 19% of pathogenic alleles. This was followed by c.592_595delACTG 
(p.Thr198Serfs*6), found in 19 alleles (14% of pathogenic alleles). The c.586C>T (p.Arg196*) 
mutation was identified in 15 alleles (11% of pathogenic alleles) and c.1075C>T (p.Arg359*) 
was reported in 10 alleles (7%). Therefore, the proportion of nonsense mutations was high, 
accounting for 78% of mutated alleles. Missense mutations occurred at a frequency of 16%, 
while the remaining mutation types were more rare. For 41 patients, information about the age 
of onset was available. Eight patients presented with a later onset of disease (> 1 year) and 33 
with an earlier onset of disease (<1 year, among them 9 patients with neonatal onset). The latest 
age of onset in this patient group was 6.5 years. Forty-seven of the 49 patient fibroblasts (not 
patient’s No. 5 and 50) which we were able to obtain showed response to OHCbl 
supplementation in the propionate fixation assay (+OHCbl/-OHCbl> 1.5). This was in line with 
similar propionate incorporation results from other publications (Lerner-Ellis et al. 2004) as 
well as the noted clinical response of cblA-type patients to vitamin B12 therapy (Matsui et al. 
1983; Hörster et al. 2007). No direct correlation could be made between the age of disease onset 
and the amount or ratio of propionate incorporation, nor between the age of disease onset and 
mutation type (data not shown). 
One third of MMAA missense mutations confer protein instability 
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Missense mutations, although the minority, are important in understanding the underlying 
biochemical mechanisms in dysfunctional MMAA. Therefore, we performed further studies of 
the defects conferred by all 22 known MMAA missense mutations, including the 9 novel 
missense mutations described here. 
Missense mutations have been described in the homozygous state, or in combination with a 
truncating allele, in 28 separate cblA-type patients (Supp. Table S1) and were localized across 
the entire polypeptide (Fig. 1A). Few mutations were found in the N-terminal extension (n=2) 
and the C-terminal dimerization arm (n=3), while most occured within the central G-domain 
(n=17) (Fig. 1A). Within this domain, one mutation (p.Thr243Asn) was located in the switch 
II motif and two mutations (p.Gly274Ser, p.Lys276Glu) were in the switch III motif. To 
investigate the contribution of each mutation to protein stability, we constructed them in two 
recombinant expression systems, human HEK293 cells and E. coli. In HEK293 cells, Western 
blot analysis of the expressed mutants, visualized as representative bands as well as normalized 
to wild-type (wt) (Fig. 1B), demonstrated very low protein levels (≤10% wt) for 7 mutant 
proteins (p.Leu89Pro, p.Arg145Gln, p.Gly147Glu, p.Ile241Phe, p.Asp258Asn, p.Ala287Asp, 
p.Gly399Val). Twelve mutant proteins showed moderately disturbed expression levels (10-
60% wt), while p.Gly192Asp and p.Thr243Asn had closer to wt levels. For E. coli expression, 
mutant protein stability was assessed following single step affinity purification (Fig. 1C). By 
this method, wt MMAA retained high protein recovery from the affinity eluant (Fig. 1C, lane 
E) compared to the total cellular lysate (Fig. 1C, lane TCL). In this assay, 6 of the 7 mutants 
identified to be unstable in HEK293 expression (p.Leu89Pro, p.Arg145Gln, p.Ile241Phe, 
p.Asp258Asn, p.Ala287Asp, p.Gly399Val), as well as p.Arg359Gln, showed very poor stability 
in E. coli, resulting in no protein recovery from the affinity eluant (Fig. 1C). Therefore, in total, 
7 out of 22 of MMAA missense mutations confer instability to the protein, agreeing with 
predictions from the FoldX server (http://foldxsuite.crg.eu/) that these mutations destabilize the 
structure (∆∆G between 3.48 and 11.15 kcal/mol). The 15 remaining mutant proteins could be 
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visualized by Coomassie staining of the SDS gel, and thus were considered to be more stable. 
These 15 mutants were bacterially expressed in large scale and purified by affinity and size 
exclusion chromatography for further investigation of their biochemical properties. 
To quantify more subtle changes to stability, the thermolability of MMAA mutants from large-
scale purification (n=15) was determined using differential scanning fluorimetry (DSF). This 
method monitors the heat-induced unfolding of proteins in the presence of a fluorescent dye in 
order to measure the melting temperature (Tm) of the purified protein (Niesen et al. 2007). The 
Tm values of thirteen mutant proteins exhibited thermal stability similar to that of wt-protein 
(having ΔTm values between -2.3 °C and +2.0 °C of the wt value of 48.5 °C, Fig. 1D, Supp. 
Table S2). Although some mutants show a slight increase in thermal stability compared to wt-
protein these values (+0.8 °C – 2.0 °C) are just outside the range of assay variability and it is 
unlikely that these mutants have a stability advantage compared to wt-protein in the cell. Two 
mutants had significantly decreased thermal stability, p.Arg98Gly exhibited a ΔTm=-3.0 °C 
while p.Asp292Val reached a ΔTm=-4.0 °C (Fig. 1D).  
GTP binding to MMAA is only reduced in a mutation located in the base-specificity loop 
The chaperone/gating function of MMAA depends on GTP-binding and GTPase activity. To 
assess the influence of MMAA missense mutations on the ability of MMAA to bind GDP and 
GMPPNP (non-hydrolysable analogue of GTP), we further utilized DSF to determine ligand-
induced Tm changes. Incubation of wt MMAA with increasing concentrations of GDP or 
GMPPNP resulted in large increases in Tm of up to 6.0 °C for GMPPNP (Fig. 2A) and 9.0 °C 
for GDP (Fig. 2B). The binding of GTP to MMAA was confirmed by using fluorescently 
labelled mant-GTP (Supp. Figure S1), from which the Kd was determined to be 35 ± 7 µM, 
which is comparable to the binding of GMPPNP to MeaB with a Kd of 7 µM (Padovani et al. 
2006). 
Measurement of the Tm values of all purified mutant proteins to determine stabilization by 
GDP/GMPPNP binding revealed only one mutation, p.Asp292Val, located in the base-
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specificity loop, a motif in the G-domain that is directly involved in nucleotide binding (Supp. 
Figure S2), that showed a strongly reduced Tm compared to wt protein in the presence of 
nucleotides (Fig. 2A and B, Supp. Table S2). This mutant showed a maximum Tm increase of 
1.8 °C for GDP and 1.6 °C for GMPPNP, indicating loss of protein stabilization due to severely 
reduced nucleotide binding (Fig. 2C, Supp. Table S2). The rest of the mutant proteins showed 
Tm changes (with vs without ligand) comparable to wt protein (GDP: 7.8-9.5 °C, GMPPNP: 
4.6-6.8 °C; Supp. Table S2). Using the curves in Fig. 2A and B we further determined the 
activation constant (AC50), a surrogate marker of the dissociation constant (Kd), for wt MMAA 
protein and each mutant for both nucleotides (Supp. Table S2). The AC50 for GDP was much 
lower than that of GMPPNP for wt MMAA (Supp. Table S2), even though Mg2+, required for 
GMPPNP binding, was supplemented in the buffer. This suggests that MMAA has a higher 
affinity for the dinucleotide form. The AC50 values of all mutant proteins were similar to wt 
MMAA for both nucleotide forms (Supp. Table S2). This includes p.Asp292Val, although the 
relatively high standard error is compatible with a poor curve fit (Supp. Table S2). In total, only 
the p.Asp292Val mutation disrupted binding of GDP/GMPPNP, while all other mutants 
displayed nucleotide binding comparable to wt MMAA protein. 
To further evaluate the contribution of the base-specificity loop to nucleotide binding, we 
generated a double mutant (p.Lys290Ala+Asp292Ala) following identification of p.Lys290 as 
a residue directly involved in nucleotide binding in the crystal structures of both human MMAA 
and its bacterial ortholog MeaB (Supp. Figure S2)(Froese et al. 2010; Lofgren et al. 2013b). As 
expected, MMAA protein harbouring p.Lys290Ala+Asp292Ala showed severely reduced 
nucleotide binding and impaired protein stabilization (Tm= 0.8 ± 0.1 °C for GDP, Tm= 0.9 ± 0.2 
for GMPPNP). Nucleotide binding evaluated using mant-GTP also confirmed impairment 
(p.Asp292Val) and loss (p.Lys290Ala+Asp292Ala) of GTP binding for the mutations (Supp. 
Figure S2). Therefore, as predicted from the crystal structure, these 2 residues are crucial for 
nucleotide binding. 
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GTPase activity stimulation by MUT is strongly impaired in all MMAA mutants 
MMAA is a G-protein belonging to the G3E family of P-loop GTPases (Leipe 2002). When 
assessed for the ability to cleave GTP into GDP and Pi, wt MMAA showed very low intrinsic 
GTPase activity, which could be highly stimulated by pre-incubation with MUT, consistent 
with published results (Froese et al. 2010) (Fig. 3A). As expected, incubation of MUT alone 
resulted in no detectable GTPase activity (Fig. 3A). Since most missense mutations are found 
in the domain responsible for GTPase activity (G-domain, Fig. 1A), we compared the activity 
of each mutant protein alone at 1000 µM GTP to that of wt enzyme. Surprisingly, all proteins 
harbouring patient missense mutations had similar intrinsic GTPase activity to wt-levels (68-
108% compared to wt-protein), with the exception of p.Arg98Gly, which substantially 
decreased activity (45% compared to wt-protein) (Fig.3B). The base-specificity loop double 
mutant p.Lys290Ala+Asp292Ala, which shows strongly reduced nucleotide binding, had 29% 
wt activity.  
Nevertheless, all mutants showed activity levels substantially, and significantly, above those in 
the assay negative control (without MMAA protein), or with the double mutant, and similar to 
that of the wt enzyme.  
The GTPase activity of wt MMAA protein after pre-incubation with MUT was strongly 
stimulated by an order of magnitude (catalytic efficiency kcat/Km= 0.123 min-1/pmol without; 
4.81 min-1/pmol with MUT stimulation), consistent with previous observations (Froese et al. 
2010) and permitting easy calculation of kinetic values. This GTPase activity stimulation by 
MUT was strongly reduced in all 15 mutants, by 3 - 150-fold compared to wt MMAA (Fig. 3C, 
Supp. Table S3). Michaelis-Menten kinetics further revealed higher Km values for all mutants 
than wt, to varying degrees (Supp. Table S3), with p.Arg98Gly and p.Gly188Arg having a Km 
of >30 times wt levels. Four mutants (p.Arg98Gly, p.Gly188Arg, p.Gly218Glu, p.Thr243Asn) 
showed a catalytic efficiency <4% of wt MMAA, while the other 11 mutants ranged between 
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6-29%. These data suggest that the functional interaction between MMAA and MUT was 
disrupted by all 15 purified mutant MMAA proteins. 
Physical interaction with MUT is abrogated in most MMAA mutants 
To assess physical interaction between MMAA and MUT, analytical size-exclusion 
chromatography was employed. MMAA migrated with an apparent molecular weight (MW) of 
80 kDa, and MUT with a MW of 215 kDa, consistent with homodimer formation in each case 
(Fig. 4A, Supp. Figure S3). When wt MMAA and MUT were pre-incubated in the presence of 
GMPPNP and Mg2+, an additional complex peak, with an apparent MW of 685 kDa, was 
identified (Fig. 4A, Supp. Figure S3). This complex peak is consistent with the presence of both 
proteins, as described previously (Froese et al. 2010). Interestingly, complex formation requires 
MMAA to be pre-bound to GMPPNP in the presence of Mg2+ for its formation, as in the absence 
of these components, no complex peak was observed (unpublished observations). All 15 
purified MMAA mutant proteins were tested by analytical size-exclusion chromatography for 
complex formation with MUT (Supp. Figure S4 and Fig. 4A). Six mutants (p.Gly192Asp, 
p.Arg196Gln, p.Glu250Lys, p.Gly274Ser, p.Lys276Glu, p.Arg359Gly) retained the ability to 
physically interact with MUT, albeit to a lesser extent than wt (Supp. Figure S4), while the 
other 9, including the 4 mutations (p.Arg98Gly, p.Gly188Arg, p.Gly218Glu, p.Thr243Asn) 
with the lowest GTPase activity stimulation, produced no detectable interaction peak. 
Information regarding each mutant protein’s ability to interact with MUT is provided in Supp. 
Table S3 and for visualization examples of a mutant protein which retains the capacity to 
interact (p.Gly192Asp) and one that did not (p.Thr243Asn) are depicted in Fig. 4A. Interaction 
between wt MMAA and MUT was confirmed in vivo by co-immunoprecipitating flag-tagged 
MMAA and endogenous MUT from MMAA transfected HEK293 cells (Fig. 4B). Importantly, 
this interaction was also dependent on the presence of Mg2+ and GMPPNP in the lysis buffer 
(Supp. Figure S5), corresponding to our in vitro findings. Under these conditions, a band 
corresponding to MUT was detected in cells expressing flag-tagged wt MMAA and, to a lesser 
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extent, p.Gly192Asp-MMAA, while no MUT protein was detected after immunoprecipitation 
with p.Thr243Asn-MMAA (Fig. 4B). These results were in accordance with our in vitro 
findings. 
Release of AdoCbl from MMAB is affected in MMAA mutants unable to bind MUT 
In the context of intracellular B12 metabolism, MMAB generates AdoCbl from ATP and 
cob(I)alamin, and directly delivers the cofactor to MUT in a transfer that is stimulated by ATP-
binding to MMAB and gated by MMAA. To further evaluate the role of MMAA in AdoCbl 
processing, we studied the release of AdoCbl from MMAB. This can be monitored 
spectrophotometrically by measuring an increase in the excitation maxima at 525 nm, consistent 
with cobalamin changing from a 5- to a 6-coordinate environment (Supp. Figure S6A) 
(Padovani et al. 2008). Titration of increasing concentrations of ATP results in a dose-
dependent release of AdoCbl from MMAB, with a Kd of 23.7 µM (Supp. Figure S6A and B). 
AdoCbl release is further favored in the presence of MUT, which accepts the transferred 
AdoCbl in a manner dependent upon direct protein-protein interactions (Padovani et al. 2008), 
resulting in a decreased Kd of 13.3 ± 1.3 µM (Supp. Figure S6B,C). In the further presence of 
apo-MMAA, or MMAA bound to GDP or GTP, the ATP-stimulated release of AdoCbl remains 
essentially unchanged (Kd’s: 8.7 ± 1.2 µM, 9.9 ± 2.4 µM and 15.1 ± 1.8 µM, respectively). 
However, in the presence of GMPPNP, which stabilizes binding between MMAA and MUT, 
the Kd for ATP-induced release of AdoCbl increases to 40.1 ± 1.9µM (Supp. Figure S6B,C). 
This suggests that MMAA binding to MUT affects the transfer of AdoCbl from MMAB, a 
result also observed in bacterial homologs (Padovani and Banerjee 2009; Lofgren et al. 2013b). 
To determine if mutant MMAA proteins affected the transfer of AdoCbl from MMAB to MUT, 
we assessed the Kd of AdoCbl release in the presence of MMAA mutants. In the presence of 
Mg2+ and GMPPNP, all mutants showed decreased Kd’s compared to MMAA wt (Fig. 5). 
Interestingly, in mutants unable to physically interact with MUT, Kd values were similar to 
those in the absence of MMAA. Mutants still able to interact with MUT showed intermediate 
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Kd values compared to the absence or presence of MMAA wt. This suggests a role for MMAA 
in the gating of the transfer of AdoCbl from MMAB to MUT, which is impaired when MMAA 
and MUT are unable to interact functionally.  
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Discussion 
As a basis for this comprehensive study on mechanisms associated with MMAA missense 
mutations we characterised 67 previously unpublished cblA-type MMA patients, including 19 
novel mutations. We found no direct correlation between age of onset and mutation type, 
suggesting other factors, such as intercurrent illness, diet or other hereditary components, may 
contribute to disease onset. In this cohort, c.433C>T (p.Arg145*) was the most frequently 
identified pathogenic allele. This mutation was also the most frequently found mutation in 
previous studies (Lerner-Ellis et al. 2004; Dempsey-Nunez et al. 2012). As in those studies, 
c.592_595delACTG (p.Thr198Serfs*6) was the second most prevalent mutation found here. 
This confirms the prominence of truncating type mutations and suggests that the complete 
absence of MMAA protein, via protein truncation, is the cause of disease in most patients with 
cblA-type MMA. On the other hand, missense mutations occurred only at a frequency of 16%. 
This is in contrast to other metabolic diseases (Mitchell et al. 2011; Caldovic et al. 2015) and 
to other proteins in the vitamin B12 pathway (Forny et al. 2016), where missense mutations 
represent the majority of identified mutations. We found it of particular interest to determine 
the mechanism by which single amino acid changes in MMAA lead to malfunction and disease. 
To this end, we analysed biochemically all 22 known missense mutations, including 9 novel 
mutations identified here. We have carried out thermostability, ligand binding, GTPase activity 
and protein interaction assays that probe the various properties of MMAA, constituting the 
largest biochemical analysis of MMAA mutations so far and found a number of mechanisms 
associated with missense mutations. These results are summarized in Table 2. 
The impact of mutations on protein stability was assessed by recombinant expression in E. coli 
and human HEK293 cells. These two expression systems showed high conformity, whereby 7 
of the 22 mutations tested in each system, 6 of which overlapped, led to destabilized protein. 
MMAA mutant proteins might be more stable in the eukaryotic expression system as additional 
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factors exclusive to eukaryotes could assist in the proper folding for certain mutants. The 
mutations are located throughout the entire polypeptide and in all three domains (Fig. 1), 
suggesting no one domain is responsible for mediating protein stability.  
Investigation of nucleotide binding showed that MMAA-wt and all mutants had a higher 
affinity for GDP than GMPPNP. This is in contrast to bacterial MeaB, which was shown to 
bind both nucleotide forms with similar affinity (Padovani et al. 2006), and is reminiscent of 
the majority of eukaryotic small GTPases which prefer GDP binding (Cherfils and Zeghouf 
2011). For example, several studies analysing GTPases of the Ras family, which serve as 
prototypes for the hydrolysis reaction of small G proteins, were shown to bind preferably to 
GDP (White et al. 2016). However, in the cellular environment, where the concentration of 
GTP is higher than GDP, these proteins are found predominantly in the GTP-bound form (Cox 
et al. 2014). Unsurprisingly, only those mutations found within the base-specificity loop of 
MMAA affected GDP/GMPPNP binding. 
We found only one mutant (Arg98Gly), located in the N-terminal extension, to cause disruption 
of the low basal GTPase activity found in wt protein. Since this mutation also caused protein 
thermolability, perhaps incomplete or improper folding affected its activity. All other mutant 
proteins had wild-type like activity, suggesting intrinsic GTPase function is not disrupted by 
the majority of MMAA mutations. This is consistent with previous investigations in MeaB and 
MMAA which found no perturbation of intrinsic GTPase activity following mutation of 
residues Gly188 (Froese et al. 2010), Thr243, Glu250 (Lofgren et al. 2013a),Gly274 or Lys276 
(Lofgren et al. 2013b) (human MMAA residue numbering). 
Although intrinsic GTPase activity of wt MMAA was shown to be very low, it could be highly 
stimulated by pre-incubation with apo-MUT (Padovani et al. 2006; Froese et al. 2010). 
However, for all mutant proteins, this stimulation was strongly inhibited. We investigated the 
physical interaction of the two proteins in vitro and in vivo to investigate if loss of interaction 
is the universal cause of impaired GTPase stimulation. Analysis of the physical interaction of 
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the two proteins in vitro and in vivo revealed 6 mutants that were still able to physically bind to 
MUT. Interestingly, 4 of those mutations (Lys276Glu, Glu250Lys, Gly274Ser, Arg359Gly) 
accounted for the highest catalytic efficiency (11.7-29.5% of wt-catalytic efficiency) of all the 
mutant proteins, suggesting that the ability to maintain physical interaction, at least partly, 
correlated with activity stimulation. The fact that some mutations resulted in abrogation of the 
physical interaction with MUT, while others left it intact, suggests that a number of mechanisms 
leading to the loss of functional interaction may be incorporated by different mutations. For 
example, some MMAA residues might be involved in the full creation of an active site during 
MUT stimulation, reminiscent of the Arg-finger in Ras-family members which stabilizes the 
transition state during GTP hydrolysis (Scheffzek et al. 1997). In this scenario, modification of 
the active site by introducing amino acid changes might cause a disturbance of charge 
distribution necessary for stabilization and thereby lead to impaired MUT stimulation. In 
addition, mutated amino acids located in positions necessary for catalysis might sterically 
impair stimulation of GTP hydrolysis. 
The lack of functional interaction, and subsequent reduced catalytic efficiency, was 
independent of the location of the mutation on the protein. We found that mutations located 
between p.Tyr207 and p.Thr243 abrogate the interaction with MUT. On the other hand, 
mutations located between p.Glu250 and p.Lys276 retain the ability to physically bind MUT. 
This suggests a correlation between the location of a mutation and its consequences on physical 
or functional interaction with MUT. The loss of functional interaction only for proteins 
containing mutations within the Switch III motif (p.Gly274Ser, p.Lys276Glu) is consistent with 
previous studies of MeaB (Lofgren et al. 2013b). The switch II region is known to be important 
in binding to effector molecules (Herrmann 2003) and indeed, the patient mutation 
p.Thr243Asn located in the switch II region caused loss of physical interaction.  
There is no structural information to date on the physical interaction between MMAA and 
MUT. The recently determined crystal structure of bacterial IcmF, a fused protein consisting of 
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MMAA- and MUT-like domains, suggests that residues 187-196 of MMAA may be important 
for physical interaction with MUT (Jost et al. 2015). Within this region, the mutant protein with 
the change of gly by arg at position 188 was unable to bind MUT in this and our previous study 
(Froese et al. 2010). We superimposed the human MMAA and MUT structures onto IcmF to 
generate an approximate model of the MMAA-MUT complex, and found that a majority of 
mutations that abrogated MUT interaction/activation are found at the putative MMAA/MUT 
interface in our model (Supp. Figure S7). Nevertheless, two mutations p.Gly192Asp and 
p.Arg196Gln that are also located in this interface did not strongly inhibit physical interaction 
between the two proteins. This is an indication that there are subtle differences in how MMAA 
and MUT interact, compared to the bacterial counterparts, that will only be resolved by future 
structural studies of the human complex. 
We found factors affecting the interaction of MMAA and MUT, it was dependent on the 
presence of Mg2+ and GMPPNP both in vitro and in vivo. Only the addition of Mg2+ and 
GMPPNP to our immunoprecipitation led to detectable interaction. This suggests that, in the 
cell, the proteins form a very weak/transient interaction that can be stabilized in the presence of 
Mg2+ and GTP. As in other G-proteins, the interaction of switch regions and the P-loop with 
phosphates and a coordinating Mg2+ ion is essential for high affinity nucleotide binding (Vetter 
and Wittinghofer 2001), which, for MMAA, might reflect the cellular prerequisites for MUT 
binding.  
MMAB, responsible for catalysing the last step of adenosylcobalamin assimilation, is also 
important for the direct transfer of AdoCbl to MUT (Padovani et al. 2008). The Kd of AdoCbl 
release from holo-MMAB in the presence of MUT was reduced in all MMAA mutants 
compared to MMAA wt, suggesting an impairment of proper gating of AdoCbl from MMAB 
to MUT. Since in the bacterial MMAA homolog MeaB gating was shown to be dependent on 
GTP hydrolysis (Padovani and Banerjee 2009), and GTPase activity stimulation was strongly 
reduced in all 15 mutants, the impairment in AdoCbl release is likely related to the decreased 
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GTPase activity of MMAA mutants. This effect was even more significant for MMAA mutants 
unable to physically interact with MUT which also showed the lowest GTPase catalytic 
efficiency. In addition to GTPase activity, the association of MUT and MMAA also plays a role 
in the gating of cofactor transfer from MMAB to MUT. 
In conclusion, our investigation of novel patients and mutations in MMAA point to the 
importance of this protein within the context of its supporting role with MUT. This outcome is 
supported by the high proportion of truncating mutations and the loss of either protein stability 
or the ability to functionally interact with MUT in the case of missense mutations. These latter 
“loss of interaction” mutations are increasingly being found in the intracellular B12 metabolic 
pathway, having already been identified in MMADHC, MMACHC (Froese et al. 2015) and 
MUT (Forny et al. 2014). This further points to complexation as required for proper B12 
pathway function, and future studies will clarify the residues required for physical and 
functional interaction, as well as how MMAB, and perhaps MCEE (methylmalonyl-CoA 
epimerase), fit into this supramolecular multi-protein machinery.  
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 Table 1. List of all 67 unpublished cblA-type patients describing sex, age of onset, propionate incorporation profiles and mutations 
Patient No. Sex Age of onset Prop. Inc. without OH-Cbla 
Prop. Inc. with 
OHCbla 
PF ratio, +/– 
OHCblb Mutation 1
c predicted changed Mutation 2c predicted changed 
1 m 3 m 1.14 4.66 4.09 c.72C>A p.Tyr24* c.72C>A p.Tyr24* 
2 f 1 m 0.97 3.93 4.05 c.202C>T p.Gln68* c.988C>T p.Arg330* 
3 m 3 m 0.20 0.95 4.75 c.267_268delTT p.Thr91Trpfs*47 c.267_268delTT p.Thr91Trpfs*47  
4 m 2 y 1.84 7.78 4.23 c.283C>T p.Gln95* c.283C>T p.Gln95* 
5 f - 2.70 3.85 1.43 c.283C>T p.Gln95* c.283C>T p.Gln95* 
6 f 6 m 1.00 3.40 3.40 c.283C>T p.Gln95* c.970-2A>T p.?. 
7 f 4 m 0.66 1.67 2.53 c.281_287delTCCAAGG p.Gln97Profs* c.433 C>T p.Arg145* 
8 m - - - - c.298_312delTGTTTAGCAGAGGCC p.Cys100_Ala104del c.298_312delTGTTTAGCAGAGGCC p.Cys100_Ala104del 
9 m - - - - c.298_312delTGTTTAGCAGAGGCC p.Cys100_Ala104del c.298_312delTGTTTAGCAGAGGCC p.Cys100_Ala104del 
10 f - 0.83 3.01 3.63 c.433C>T p.Arg145* c.433C>T p.Arg145* 
11 m - - - - c.433C>T p.Arg145* c.433C>T p.Arg145* 
12 f - - - - c.433C>T p.Arg145* c.433C>T p.Arg145* 
13 f - - - - c.433C>T p.Arg145* c.433C>T p.Arg145* 
14 f 6 m 1.12 4.44 3.96 c.433C>T p.Arg145* c.433C>T p.Arg145* 
15 f neonatal 0.95 5.40 5.68 c.433C>T p.Arg145* c.433C>T p.Arg145* 
16 f - - - - c.433C>T p.Arg145* c.433C>T p.Arg145* 
17 f 8 m 1.19 6.45 5.42 c.433C>T p.Arg145* c.433C>T p.Arg145* 
18 m - - - - c.433C>T p.Arg145* c.433C>T p.Arg145* 
19 m - 0.70 - - c.433C>T p.Arg145* c.434G>A p.Arg145Gln 
20 m 14 m 0.94 4.97 5.29 c.433C>T p.Arg145* c.450dupG p.Pro151Alafs* 
21 m 10 m 1.00 4.34 4.34 c.433C>T p.Arg145* c.551dupG p.Cys184Trpfs*3 
22 f 4 y 1.34 5.52 4.12 c.433C>T p.Arg145* c.592_595delACTG p.Thr198Serfs*6 
23 f 6 m 0.90 4.70 5.22 c.433C>T p.Arg145* c.733+5G>A p.?. 
24 f neonatal 1.06 5.04 4.75 c.433C>T p.Arg145* c.875A>T  p.Asp292Val 
25 f neonatal 1.65 4.78 2.90 c.441dupA p.Leu148Ilefs*22 c.441dupA p.Leu148Ilefs*22 
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26 f - 0.42 1.70 4.03 c.455delC p.Pro152Leufs*9 c.455delC p.Pro152Leufs*9 
27 m neonatal 0.69 3.31 4.80 c.455delC p.Pro152Leufs*9 c.455delC p.Pro152Leufs*9 
28 m 6 m 1.40 5.40 3.86 c.455delC p.Pro152Leufs*9 c.455delC p.Pro152Leufs*9 
29 m 11 m 0.73 4.11 5.63 c.527_528delTG p.Val176Alafs* c.527_528delTG p.Val176Alafs* 
30 m neonatal 1.46 4.81 3.29 c.527_528delTG p.Val176Alafs* c.527_528delTG p.Val176Alafs* 
31 m 6 m 0.83 2.01 2.42 c.551dupG p.Cys184Trpfs*3 c.433C>T p.Arg145* 
32 m - - - - c.551dupG p.Cys184Trpfs*3 c.592_595delACTG p.Thr198Serfs*6 
33 m 5 d 0.28 1.13 3.99 c.575G>A  p.Gly192Asp c.575G>A p.Gly192Asp 
34 f - - - - c.586C>T  p.Arg196* c.586C>T p.Arg196* 
35 m 3 d 0.99 3.96 4.00 c.586C>T  p.Arg196* c.586C>T p.Arg196* 
36 f - - - - c.586C>T  p.Arg196* c.586C>T p.Arg196* 
37 f neonatal 0.84 4.76 5.67 c.586C>T  p.Arg196* c.586C>T p.Arg196* 
38 m - - - - c.586C>T  p.Arg196* c.586C>T p.Arg196* 
39 m 6 w 1.26 4.98 3.95 c.586C>T  p.Arg196* c.586C>T p.Arg196* 
40 f 3 d 0.88 4.13 4.69 c.586C>T  p.Arg196* c.592_595delACTG p.Thr198Serfs*6 
41 m neonatal 0.94 3.26 3.47 c.586C>T  p.Arg196* c.592_595delACTG p.Thr198Serfs*6 
42 m 3 d 1.00 4.53 4.53 c.586C>T  p.Arg196* c.1196_1197delinsTT  p.Gly399Val 
43 m neonatal 1.33 6.16 4.63 c.[587G>A; 733+1G>A] p.Arg196Gln/p.?. c.[587G>A; 733+1G>A] p.Arg196Gln/p.?. 
44 f 3 y2 m 1.09 3.79 3.48 c.592_595 delACTG p.Thr198Serfs*6 c.592_595delACTG p.Thr198Serfs*6 
45 f - 1.10 5.90 5.36 c.592_595delACTG p.Thr198Serfs*6 c.592_595delACTG p.Thr198Serfs*6 
46 m - 1.96 5.76 2.94 c.592_595delACTG p.Thr198Serfs*6 c.592_595delACTG p.Thr198Serfs*6 
47 f 3 d 1.04 5.13 4.93 c.592_595delACTG p.Thr198Serfs*6 c.592_595delACTG p.Thr198Serfs*6 
48 f - 1.40 4.00 2.86 c.592_595delACTG p.Thr198Serfs*6 c.592_595delACTG p.Thr198Serfs*6 
49 m neonatal 1.77 5.45 3.08 c.592_595delACTG p.Thr198Serfs*6 c.592_595delACTG p.Thr198Serfs*6 
50 m 5 d 2.43 3.11 1.28 c.592_595 delACTG p.Thr198Serfs*6 c.820-1G>A p.?. 
51 f 2.5 y 1.61 4.53 2.82 c.592_595delACTG  p.Thr198Serfs*6 c.721A>T p.Ile241Phe 
52 m 5.5 m 1.69 4.99 2.95 c.592_595delACTG  p.Thr198Serfs*6 c.860C>A  p.Ala287Asp 
53 m 3.5 m 2.32 4.86 2.09 c.651dupA p.Gly218Argfs* c.988C>T p.Arg330* 
54 f 14 m 3.32 8.54 2.58 c.658G>A  p.Val220Met c.658G>A  p.Val220Met 
55 m - - - - c.658G>A  p.Val220Met c.658G>A  p.Val220Met 
56 f 1.2 y 1.43 4.44 3.10 c.728C>A p.Thr243Asn c.728C>A p.Thr243Asn 
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57 f 21 m 1.31 3.43 2.63 c.733+1G>A p.?. c.733+1G>A p.?. 
58 f 3 d 1.00 3.00 3.00 c.742C>T p.Glu248* c.742C>T p.Glu248* 
59 f 3 m 2.30 7.60 3.30 c.772G>A  p.Asp258Asn c.772G>A  p.Asp258Asn 
60 m - - - - c.772G>A  p.Asp258Asn c.772G>A  p.Asp258Asn 
61 m 3 y - - - c.1034delT p.Phe345Serfs*4 c.1034delT p.Phe345Serfs*4 
62 f - - - - c.1075C>T p.Arg359* c.1075C>T p.Arg359* 
63 f - - - - c.1075C>T p.Arg359* c.1075C>T p.Arg359* 
64 f - 1.21 3.76 3.11 c.1075C>T p.Arg359* c.1075C>T p.Arg359* 
65 f 5 d 1.86 4.77 2.56 c.1075C>T p.Arg359* c.1075C>T p.Arg359* 
66 m - - - - c.1075C>T p.Arg359* c.1075C>T p.Arg359* 
67 m 6.5 y 0.90 3.00 3.33 c.1076G>A p.Arg359Gln c.1076G>A p.Arg359Gln 
          
 
All unpublished mutations are depicted in bold, all missense mutations are depicted in italic. 
a Results for mutase activity which was assessed indirectly using [14C]- propionate incorporation (nmol/mg protein/16h) in cultured skin fibroblasts grown in presence or absence of hydroxocobalamin (OHCbl, 1 or 10 mg/L). Reference rages for 
Prop. Inc. without OHCbl 5.2-22.0; with OHCbl 5.7-31.7 
bRatio of incorporated propionate to phenylalanine (PF-atio) was calculated. Reference range 0.93-1.69 
c According to NM_172250.2 and NC_000004.12. Nucleotide numbering uses +1 as the A of the ATG translation initiation codon in the reference sequence, with the initiation codon as codon 1.  
d According to NP_758454.1   
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Table 2. Summary of biochemical results for all investigated MMAA mutants 
 
 
 
mutation protein stability 
GTP 
binding 
intrinsic GTPase 
activity catalytic efficiency 
interaction 
with MUT 
Kd AdoCbl 
release 
      % compared to wt kcat/Km (min-1/pmol)  µM 
wt yes normal 100 4.81 yes 42.6 ± 2.5 
L89P no - - - - - 
R98G yes normal 45.6 ± 8.1 0.049 no 9.6 ± 1.4 
R145Q no - - - - - 
G147E yes normal 88.1 ± 8.5 0.463 no 9.2 ± 0.4 
G188R yes normal 100 ± 5.6 0.0317 no 7.8 ± 2.1 
G192D yes normal 97.1 ± 26.7 0.454 yes 16.6 ± 2.3 
R196Q yes normal 100.6 ± 8.7 0.297 yes 24.1 ± 1.6 
Y207C yes normal 75.3 ± 13.8 0.355 no 7.8 ± 0.5 
R209S yes normal 81.1 ± 8.7 0.407 no 8.4 ± 0.7 
G218E yes normal  0.059 no 7.4 ± 0.4 
V220M yes normal 103.4 ± 21.3 0.384 no 11 ± 1.6 
I241F no - - - - - 
T243N yes normal 92.8 ± 12.5 0.149 no 9.0 ± 0.9 
E250K yes normal 107.8 ± 6.4 0.611 yes 14.7 ± 1.2 
D258N no - - - - - 
G274S yes normal 67.9 ± 5.9 0.759 yes 35.1 ± 5.5 
K276E yes normal 75.6 ± 9.6 0.565 yes 16.4 ± 2.6 
A287D no - - - - - 
D292V yes decreased 78.3 ± 1.0 0.409 no 11.4 ± 1.9 
R359G yes normal 101.4 ± 8.7 1.42 yes 14.2 ± 3.5 
R359Q no - - - - - 
G399V no - - - - - 
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Figure Legends: 
Fig. 1: Effects of MMAA missense mutations on protein stability A: Above: Domain 
organization of MMAA highlighting locations of the studied mutations, N-terminal extension, 
G domain and C-terminal dimerization arm. Unpublished mutations are depicted in green. 
Below: Sites of missense mutations mapped onto one subunit of the human MMAA homodimer 
(PDB code: 2www). Coloured subunit is shown in purple for N-terminal extension, yellow for 
GTPase domain and blue for dimerization arm. Residues known to harbour missense mutations 
are represented either as red spheres if they are present in the structure, or are grouped in loop 
regions where the structure is disordered. B: Western blot following expression of each MMAA 
mutant in HEK293 cells. Results are the mean ± s.d. (n=3). C: Coomassie staining of SDS-
PAGE following small-scale bacterial expression and affinity purification of MMAA. For wt, 
lanes for total cell lysate (TLC) and eluant (E) after purification are shown. For each mutant 
protein only eluant is shown. D: Thermolability of MMAA mutations. The change in Tm values 
(ΔTm, compared with wt) for each mutant is shown. Results are the mean ± s.d. (n=6). 
 
Figure 2. GTP binding of mutants. A and B: The change in Tm following incubation of wt 
MMAA (circles) or D292V (squares) with increasing concentrations of GDP (5-2000 µM) or 
GMPPNP (50-5000 µM). Each data point represents the mean ± s.d. (n=3). Curves were fitted 
using One Site – Total binding using GraphPad Prism (v6.07). C: Analysis of stabilization by 
DSF of wt MMAA and D292V following incubation with 1 mM GMPPNP or GDP. Each curve 
represents the mean of n = 3 experiments.  
 
Figure 3. GTPase activity of MMAA mutants. A: Effect of MUT on the GTPase activity of 
MMAA. MMAA (20 µM) pre-incubated with MUT (20 µM, rectangle), without MUT (circle), 
or MUT alone (20 µM, triangle) was incubated in the presence of varying concentrations of 
GTP (100–2500  µM). B: Intrinsic GTPase activity of MMAA mutants compared to wt. GTPase 
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assays were carried out in the presence of 1000 µM GTP. Results are the mean ± s.d. (n=3). C: 
Catalytic efficiency of MMAA mutants. wt MMAA or mutants (20 µM) were pre-incubated 
with MUT (20 µM) in presence of varying concentrations of GTP (100–2000 µM). Kinetic 
parameters of GTP hydrolysis are shown in Supp. Table S2. 
 
Figure 4. Interaction of MMAA mutants and MUT. A: Gel filtration profiles of wt MMAA 
alone (dashed), MUT alone (dotted) or wt MMAA pre-incubated with MUT (light grey) and 
representative MMAA mutants physically interacting (MMAA G192D, dark grey) or not 
interacting (MMAA T243N, black) with MUT analysed on a HiLoad 10/30 Superdex 200 
column. The complex peak as well as individual protein peaks are labelled. Interaction results 
of all MMAA mutants are summarized in Supp. Table S2. B: Co-Immunoprecipitation of Flag-
tagged wt MMAA and representative Flag-tagged MMAA mutants interacting (MMAA 
G192D) or not interacting (MMAA T243N) with MUT in HEK293 cells. Western Blot analysis 
of anti-Flag immunoprecipitates (flag), control IgG (IgG) and input lysates (Input, lower panel) 
with anti-Flag or anti-MUT is shown.  
 
Figure 5. Release of AdoCbl from MMAB is affected in MMAA mutants. Bargraphs 
represent the Kd values of AdoCbl released from holo-MMAB (60 μM) in the presence of 
MUT (60 μM, no MMAA) and MUT (60 μM) plus wt MMAA or MMAA mutants (60 μM) 
supplemented with 0.5 mM GMPPNP. MMAA mutants able to bind to MUT are in dark grey 
while non-binding mutants are in light grey. 
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